A phase 2 randomized open-label study of patritumab deruxtecan (U3-1402) in subjects with previously treated metastatic or locally advanced EGFR mutated non-small cell lung cancer (NSCLC) (HERTHENA-Lung01)

UVA Tracking #
HSR210052
Principal Investigator
Ryan Gentzler
Contact
Lacey Botteon
Contact Phone
434.297.5588
Official Trial Title
HERTHENA-Lung01: A Phase 2 Randomized Open-Label
Study of Patritumab Deruxtecan (U3-1402) in Subjects with
Previously Treated Metastatic or Locally Advanced EGFRmutated
Non-Small Cell Lung Cancer (NSCLC)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have non-small cell lung cancer with an EGFR mutation. The purpose of this study to evaluate an investigational drug (patritumab deruxtecan) at varying doses in patients with non-small cell lung cancer. The effects of the investigational drug will be evaluated for this study.

Participation includes pre-screening tissue collection, a screening period, 3 week cycles of treatment, with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study as long as the treatment is still helping your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04619004

Compensation

You will receive $50 per study visit. You will receive up to $175 for hotel stays per night.